Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131141 | 0.92 | POLB (0.42) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6135690 | 0.72 | CYP3A4 (0.43) | POLBMEN1KMT2AALDH1A1SLC6A2 | |
| SCHEMBL7229504 | 0.71 | DPP4 (0.39) | SLC6A2 | |
| SCHEMBL7049996 | 0.71 | CTSL (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11010892 | 0.70 | CYP3A4 (0.46) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4314794 | 0.69 | PKM (0.44) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4317705 | 0.69 | PKM (0.44) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6098576 | 0.69 | SLC1A3 (0.42) | POLBMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7407155 | 0.69 | APOBEC3A (0.46) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13672306 | 0.68 | TSHR (0.44) | POLBMEN1KMT2AALDH1A1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131707-A1 | CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-7452999-B2 | Chemical process for the preparation of intermediates to obtain N-formyl hydroxy-lamine compounds | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| CN-101092342-A | Chemical process for the preparation of intermediates to obtain n-formyl hydroxy-lamine compounds | NOVARTIS AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| US-20070179298-A1 | Chemical process for the preparation of intermediates to obtain n-formyl hydroxy-lamine compounds | NOVARTIS AG (CH) | 2007-08-02 | — | — | US | disclosed |
| CN-1759097-A | Chemical process for preparing intermediates for obtaining N-formyl hydroxylamines | NOVARTIS AG (CH) | 2006-04-12 | — | — | CN | disclosed |
| EP-1599440-A2 | CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076053-A2 | CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131707-A1 | CHEMICAL PROCESS FOR THE PREPARATION OF INTERMEDIATES TO OBTAIN N-FORMYL HYDROXYLAMINE COMPOUNDS | HAO2, HAO1, HAAO | POLB 287/4885MEN1 3891/4885KMT2A 3306/4885 |
| US-20070179298-A1 | Chemical process for the preparation of intermediates to obtain n-formyl hydroxy-lamine compounds | HAO1, LMNA, HAO2 | POLB 150/4885MEN1 3412/4885KMT2A 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.